BRCA2 deletion
|
Ovarian Cancer
|
BRCA2 deletion
|
Ovarian Cancer
|
bevacizumab Sensitive: C3 – Early Trials
Cancer - 1 week (New C3)
|
bevacizumab Sensitive: C3 – Early Trials
Cancer - 1 week - (New C3)
|
BRCA2 deletion
|
Prostate Cancer
|
BRCA2 deletion
|
Prostate Cancer
|
enzalutamide capsule Sensitive: B - Late Trials
|
enzalutamide capsule Sensitive: B - Late Trials
|
BRCA2 deletion
|
Prostate Cancer
|
BRCA2 deletion
|
Prostate Cancer
|
abiraterone acetate Sensitive: B - Late Trials
|
abiraterone acetate Sensitive: B - Late Trials
|
BRCA2 deletion
|
Prostate Cancer
|
BRCA2 deletion
|
Prostate Cancer
|
rucaparib Sensitive: C3 – Early Trials
|
rucaparib Sensitive: C3 – Early Trials
|
BRCA2 deletion
|
Ovarian Cancer
|
BRCA2 deletion
|
Ovarian Cancer
|
rucaparib Sensitive: C3 – Early Trials
|
rucaparib Sensitive: C3 – Early Trials
|
BRCA2 deletion
|
Prostate Cancer
|
BRCA2 deletion
|
Prostate Cancer
|
olaparib Sensitive: C3 – Early Trials
|
olaparib Sensitive: C3 – Early Trials
|
BRCA2 deletion
|
Squamous Cell Skin Cancer
|
BRCA2 deletion
|
Squamous Cell Skin Cancer
|
pembrolizumab Sensitive: C4 – Case Studies
|
pembrolizumab Sensitive: C4 – Case Studies
|
BRCA2 deletion
|
Prostate Cancer
|
BRCA2 deletion
|
Prostate Cancer
|
ACR-368 Sensitive: D – Preclinical
|
ACR-368 Sensitive: D – Preclinical
|